#United States #Salt Lake City #Sera Prognostics #Maternal Health #PreTRM Test

Sera Prognostics to Host Conference Call for Q3 Financial Results

Sera Prognostics Inc., widely recognized as The Pregnancy Company®, announced plans to provide updates on its Q3 fiscal year 2026 financial results during a conference call set for November 4, 2026, after market close. This conference call is an essential avenue for the company to share its achievements, financial results, and significant topics with stakeholders.

Empowering Maternal and Neonatal Health

Sera Prognostics is devoted to enhancing both maternal and neonatal health through innovative diagnostic solutions. Their focus on delivering essential pregnancy biomarker information empowers healthcare practitioners and patients alike. The company's signature product, the PreTRM® Test, stands out as a critical tool that aids clinicians in forecasting the risk of preterm births, allowing for proactive patient care.

Conference Call Details

The scheduled conference call will take place at 5:00 PM Eastern Time on November 4. Participants can join by calling:

• - U.S. Domestic Callers: (800) 836-8184
• - International Callers: (646) 357-8785

A live audio stream will also be available on Sera Prognostics' Investors page. A press release summarizing financial results will precede this call, aiding investor understanding and engagement.

Webcast Registration and Availability

Stakeholders wishing to participate can register via a link provided in the company's announcement. Following the live event, the webcast will be archived on the Investors section of their website for one year, ensuring extended access for interested parties.

Insights and Innovations

Sera Prognostics continues to lead in the field of maternal health with a commitment to providing vital information that can significantly improve pregnancy outcomes. The PreTRM® test, in particular, is lauded as the only broadly validated blood-based biomarker test in the market capable of delivering individualized risk predictions for spontaneous preterm birth in asymptomatic singleton pregnancies. By analyzing specific proteins in the blood, this test empowers medical professionals to make informed decisions, ultimately leading to better health outcomes for mothers and infants.

The Challenge of Preterm Birth

Preterm birth, defined as a birth that occurs before 37 weeks of gestation, remains a pressing public health issue. It is the leading cause contributing to complications and mortality in newborns. The statistic underscores a critical need for proactive and predictive healthcare solutions. Data from the March of Dimes Report Card in 2025 highlights this issue, revealing a continued D+ grade for the U.S. in terms of preterm birth rates. The lasting effects of preterm birth can lead to a host of medical challenges, including learning disabilities and chronic illnesses, making preventative measures and timely interventions essential.

Through their forward-thinking approach, Sera Prognostics is striving to address these issues significantly while reducing healthcare costs associated with maternal and neonatal care. The company is currently headquartered in Salt Lake City, Utah, where its operations center around the mission of improving health outcomes through innovation and precision.

Conclusion

As Sera Prognostics approaches the date of its Q3 fiscal year 2026 financial results announcement, healthcare stakeholders are encouraged to stay tuned for insights on their progress and the critical role they play in advancing maternal health. This forthcoming conference call provides an excellent opportunity to gain valuable information that aligns with the shared goal of enhancing the health and well-being of women and babies across the nation.